771 related articles for article (PubMed ID: 9340970)
21. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
22. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacotherapy in ovarian carcinoma].
Pfisterer J; Du Bois A
MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
[TBL] [Abstract][Full Text] [Related]
24. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
25. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide in the treatment of ovarian cancer.
Markman M
Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
[TBL] [Abstract][Full Text] [Related]
30. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of recurrent ovarian cancer--a retrospective study].
Tkácová M; Belohorská B; Sevcíková K; Hel'pianska L; Ondrus D; Ondrusová M; Spánik S
Klin Onkol; 2010; 23(2):115-23. PubMed ID: 20465091
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
33. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
35. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
[TBL] [Abstract][Full Text] [Related]
36. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
38. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
39. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
40. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
